A Venture Capitalist Goes to Washington: Doug Kelly’s FDA Awakening

article image
ARTICLE SUMMARY:

Doug Kelly has spent decades investing in and founding new medtech companies, viewing FDA as more of a barrier than an accelerator to innovation. But his career recently took an unexpected turn—Kelly is CDRH’s new deputy director for science. He says the role offers a chance to help improve the medtech ecosystem, making it a place where more investors want to play. So far, Kelly tells Market Pathways, the job is going very well: “The people at FDA are amazing."

After 30 years as a founder and venture capitalist, Doug Kelly, MD, was at a crossroads. With his two venture fund partners retiring, he first considered the more obvious next career steps for someone in his position, such as starting a new fund or founding a company. Kelly got to work with a few others discussing the planning stages of a start-up. Ultimately, however, those plans never got off the ground.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: